Genetic background of coronary artery disease: clinical implications and perspectives

References

• Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232–3245.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019:pii: ehz425. DOI:10.1093/eurheartj/ehz425.
   PubMedGoogle Scholar
• Stitziel NO, Stirrups KE, Masca NG, et al.; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374:1134–1144.
   PubMed Web of Science ®Google Scholar
• Webb TR 1, Erdmann J 2, Stirrups KE 3, et al.; Myocardial infarction genetics and CARDIoGRAM exome consortia investigators. Systematic evaluation of pleiotropy identifies six further loci associated with coronary artery disease. J Am Coll Cardiol. 2017;69:823–836.
   PubMed Web of Science ®Google Scholar
• Mecchia D, Lavezzi AM, Mauri M, et al. Feto-placental atherosclerotic lesions in intrauterine fetal demise: role of parental cigarette smoking. Open Cardiovasc Med J. 2009;3:51–56.
   PubMedGoogle Scholar
• Sakakura K, Nakano M, Otsuka F, et al. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 2013;22:399–411.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol. 2014;9:73–102.
   PubMed Web of Science ®Google Scholar
• Crea F, Liuzzo G. Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. Eur Heart J. 2016;37(30):2414–2416.
   PubMed Web of Science ®Google Scholar
• Visscher PM, Hill WG, Wray NR. Heritability in the genomics era – concepts and misconceptions. Nat Rev Genet. 2008;9:255–266.
   PubMed Web of Science ®Google Scholar
• Chial H. Mendelian genetics: patterns of inheritance and single-gene disorders. Nat Educ 2013 Nov 4;1(1):2008. Available from: http://www.nature.com/scitable/topicpage/mendelian-genetics-patterns-ofinheritance-and-single-966
   Google Scholar
• Lobo I. Multifactorial inheritance and genetic disease. Nat Educ 2013 Nov 4;1(1):2008. Available from: http://www.nature.com/scitable/topicpage/multifactorial-inheritance-and-genetic-disease-919
   Google Scholar
• Elosua R, Lluis-Ganella C, Lucas G. Research into the genetic component of heart disease: from linkage studies to genome-wide genotyping. Rev Esp Cardiol Suppl. 2009;9(Suppl):24B–38B.
   Google Scholar
• Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005;45:907–913.
   PubMed Web of Science ®Google Scholar
• Visscher PM, Brown MA, McCarthy MI, et al. Five years of GWAS discovery. Am J Hum Genet. 2012 Jan 13;90(1):7–24.
   PubMed Web of Science ®Google Scholar
• Sayols-Baixeras S, Lluís-Ganella C, Lucas G, et al. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet. 2014;16(7):15–32.
   Google Scholar
• Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015 Oct;47(10):1121–1130.
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491–1493.
   PubMed Web of Science ®Google Scholar
• McPherson R. Chromosome 9p21.3 locus for coronary artery disease: how little we know. J Am Coll Cardiol. 2013;62(15):1382–1383.
   PubMed Web of Science ®Google Scholar
• McVicker G, van de Geijn B, Degner JF, et al. Identification of genetic variants that affect histone modifications in human cells. Science. 2013;342:747–749.
   PubMed Web of Science ®Google Scholar
• Consortium, ENCODE Project. A user’s guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 2011;9:e1001046.
   PubMed Web of Science ®Google Scholar
• Miller CL, Anderson DR, Kundu RK, et al. Disease-related growth factor and embryonic signaling pathways modulate an enhancer of TCF21 expression at the 6q23.2 coronary heart disease locus. PLoS Genet. 2013;9:e1003652.
   PubMed Web of Science ®Google Scholar
• Wild PS, Zeller T, Schillert A, et al. A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet. 2011;4:403–412.
   PubMed Web of Science ®Google Scholar
• Reilly MP 1, Li M, He J, et al. Wellcome Trust Case CIdentification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377(9763):383–392.
   PubMed Web of Science ®Google Scholar
• Wang L, Zheng J, Bai X, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res. 2009;104(5):688–698.
   PubMed Web of Science ®Google Scholar
• Bauer RC, Tohyama J, Cui J, et al. Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice. Circulation. 2015;131:1202–1213.
   PubMed Web of Science ®Google Scholar
• Nurnberg ST, Cheng KR, Raiesdana A, et al. Coronary artery disease associated transcription factor tcf21 regulates smooth muscle precursor cells that contribute to the fibrous cap. PLoS Genet. 2015;11:e1005155.
   PubMed Web of Science ®Google Scholar
• Dichgans M, Malik R, König IR, et al.; METASTROKE Consortium. Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. Stroke. 2014;45:24–36.
   PubMed Web of Science ®Google Scholar
• Feil R, Kemp-Harper B. cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep. 2006;7:149–153.
   PubMed Web of Science ®Google Scholar
• Acharya A, Baek ST, Huang G, et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development. 2012;139:2139–2149.
   PubMed Web of Science ®Google Scholar
• Braitsch CM, Combs MD, Quaggin SE, et al. Pod1/Tcf21 is regulated by retinoic acid signaling and inhibits differentiation of epicardium-derived cells into smooth muscle in the developing heart. Dev Biol. 2012;368:345–357.
   PubMed Web of Science ®Google Scholar
• Strong A, Ding Q, Edmondson AC, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012;122:2807–2816.
   PubMed Web of Science ®Google Scholar
• CARDIoGRAMplusC4D Consortium. Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33.
   PubMed Web of Science ®Google Scholar
• Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–169.
   PubMed Web of Science ®Google Scholar
• O’Donnell CJ, Kavousi M, Smith AV, et al.; Consortium, CARDIoGRAM. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation. 2011;124:2855–2864.
   PubMedGoogle Scholar
• Wang AZ, Li L, Zhang B, et al. Association of SNP rs17465637 on chromosome 1q41 and rs599839 on 1p13.3 with myocardial infarction in an American Caucasian population. Ann Hum Genet. 2011;75:475–482.
   PubMed Web of Science ®Google Scholar
• Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714–719.
   PubMed Web of Science ®Google Scholar
• Kjolby M, Andersen OM, Breiderhoff T, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12:213–223.
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–197.
   PubMed Web of Science ®Google Scholar
• Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–713.
   PubMed Web of Science ®Google Scholar
• Satoh T, Kidoya H, Naito H, et al. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 2013;495:524–528.
   PubMed Web of Science ®Google Scholar
• Hanna RN, Shaked I, Hubbeling HG, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res. 2012;110:416–427.
   PubMed Web of Science ®Google Scholar
• Kraja AT, Chasman DI, North KE, et al. Pleiotropic genes for metabolic syndrome and inflammation. Mol Genet Metab. 2014;112:317–338.
   PubMed Web of Science ®Google Scholar
• Wiegman A, Gidding SS, Watts GF, et al.; European Atherosclerosis Society Consensus. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425–2437.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al., Investigators. Open-label study of long-term evaluation against LDL cholesterol (OSLER). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598–607.
   PubMed Web of Science ®Google Scholar
• Jin L, Lin X, Yang L, et al. AK098656, a novel vascular smooth muscle cell-dominant long noncoding RNA, promotes hypertension. Hypertension. 2018;71(2):262–272.
   PubMed Web of Science ®Google Scholar
• Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019 pii: ehz430. DOI: 10.1093/eurheartj/ehz430.
   Google Scholar
• Cole CB, Nikpay M, McPherson R. Gene-environment interaction in dyslipidemia. Curr Opin Lipidol. 2015;26:133–138.
   PubMed Web of Science ®Google Scholar
• Man HSJ, Sukumar AN, Lam GC, et al. Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA. Proc Natl Acad Sci U S A. 2018;115(10):2401–2406.
   PubMed Web of Science ®Google Scholar
• Cheng HS, Njock MS, Khyzha N, et al. Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation. Front Genet. 2014;5:422.
   PubMed Web of Science ®Google Scholar
• Neumann P, Jaé N, Knau A, et al. The lncRNA GATA6-AS epigenetically regulates endothelial gene expression via interaction with LOXL2. Nat Commun. 2018;9(1):237.
   PubMedGoogle Scholar
• Wu G, Cai J, Han Y, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 2014;130(17):1452–1465.
   PubMed Web of Science ®Google Scholar
• Boulberdaa M, Scott E, Ballantyne M, et al. A role for the long non coding RNA SENCR in commitment and function of endothelial cells. Mol Ther. 2016;24(5):978–990.
   PubMed Web of Science ®Google Scholar
• Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial disease. Blood. 2000;95:1517–1532.
   PubMed Web of Science ®Google Scholar
• Di Castelnuovo A, D’Orazio A, Amore C, et al. Genetic modulation of coagulation factor. VII. Plasma levels: contribution of different polymorphisms and gender-related effects. Thromb Haemost. 1998;80:592–597.
   PubMed Web of Science ®Google Scholar
• Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91:755–763.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Howard T, Florance A, et al. Estrogen receptor polymorphisms associated with enhanced response of HDL to estrogen replacement therapy in postmenopausal women, circulation, 2001. Circulation. 2001;103:1353. ( abstract).
   Web of Science ®Google Scholar
• Sesso HD, Lee IM, Gaziano JM, et al. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104(4):393–398.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. ESC scientific document group, 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention. Eur Heart J. 2016;37(29):2315–2381.
   PubMed Web of Science ®Google Scholar
• Marrugat J, Vila J, Baena-Díez JM, et al. Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study. Rev Esp Cardiol. 2011;64(5):385–394.
   PubMed Web of Science ®Google Scholar
• Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349–2358.
   PubMed Web of Science ®Google Scholar
• Ripatti S, Tikkanen E, Orho-Melander M, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376(9750):1393–1400.
   PubMed Web of Science ®Google Scholar
• Perelshtein Brezinov O, Kivity S, Segev S, et al. Gender-related cardiovascular risk in healthy middle-aged adults. Am J Cardiol. 2016;118(11):1669–1673.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. New Engl J Med. 1999;340:1801–1811.
   PubMed Web of Science ®Google Scholar
• Armeni E, Lambrinoudaki I. Androgens and cardiovascular disease in women and men. Maturitas. 2017;104:54–72.
   PubMed Web of Science ®Google Scholar
• Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary disease in women. New Engl J Med. 1987;316:1105–1110.
   PubMed Web of Science ®Google Scholar
• Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American heart association. Circulation. 2001;104:499–503.
   PubMed Web of Science ®Google Scholar
• Silander K, Alanne M, Kristiansson K, et al. Gender differences in genetic risk profiles for cardiovascular disease. PLoS One. 2008;3(10):e3615.
   PubMed Web of Science ®Google Scholar
• Miserez AR, Keller U. MiDifferences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscl Thromb Vasc Biol. 1995;15:1719–1729.
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Okatani Y, Ikenoue N. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis. 2000;150:103–111.
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Peloso GM, Pencina MJ, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham heart study. Circ Cardiovasc Genet. 2012;5(1):113–121.
   PubMedGoogle Scholar
• Khera. AV, Chaffin M, Zekavat SM. Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. Circulation. 2019;139:1593–1602.
   PubMed Web of Science ®Google Scholar
• Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol. 2018;72(16):1883–1893.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Viera AJ, Krantz MJ, et al. Cardiovascular Health Intervention Research and Translation Network Work Group on Global Coronary Heart Disease Risk. The effect of giving global coronary risk information to adults: a systematic review. Intern Med. 2010;170:230–239.
   Google Scholar
• Kullo IJ, Jouni H, Olson JE, et al. Design of a randomized controlled trial of disclosing genomic risk of coronary heart disease: the Myocardial Infarction Genes (MI-GENES) study. BMC Med Genomics. 2015;8:51.
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538–549.
   PubMed Web of Science ®Google Scholar
• Marin F, Gonzalez-Conejero R, Capranzano P, et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54:1041–1057.
   PubMed Web of Science ®Google Scholar
• Verschuren JJ, Trompet S, Wessels JA, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J. 2012;33:165–175. **Review on pharmacogenetics in CV disease.
   PubMed Web of Science ®Google Scholar
• Taylor AL, Ziesche S, Yancy C, et al. AfricanAmerican Heart Failure Trial. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) Study. Am J Cardiol. 2006;97:843–850.
   PubMed Web of Science ®Google Scholar
• Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol. 2012;60:9–20.
   PubMed Web of Science ®Google Scholar
• Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008;51:449–455.
   PubMed Web of Science ®Google Scholar
• Hopewell JC, Parish S, Clarke R, et al. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol. 2011;57:2000–2007.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy – a genomewide study. N Engl J Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122–130.
   PubMed Web of Science ®Google Scholar
• Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007;115:2490–2496.
   PubMed Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66:222–232.
   PubMed Web of Science ®Google Scholar
• Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371–376.
   PubMed Web of Science ®Google Scholar
• Hall KT, Nelson CP, Davis RB, et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:2160–2167.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–857.
   PubMed Web of Science ®Google Scholar
• Mega JL, Hochholzer W, Frelinger AL III, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221–2228.
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Becker RC and investigators, PLATO. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Concato J, Brophy M, et al.; Million veteran program (MVP). A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol. 2016;70:214.
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376:1312–1319.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the ESC and of the EACTS. Eur Heart J. 2018 Jan;39(3):213–260.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427–2434.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–2293.
   PubMed Web of Science ®Google Scholar
• Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing–recalibrating expectations. N Engl J Med. 2013;369:2273–2275.
   PubMed Web of Science ®Google Scholar
• Mega JL, Walker JR, Ruff CT, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2280–2287.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:pii: ehz455.
   Web of Science ®Google Scholar
• Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662–664.
   PubMed Web of Science ®Google Scholar
• Haycock PC, Heydon EE, Kaptoge S, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2014 Jul 8;349:g4227.
   PubMed Web of Science ®Google Scholar
• van der Harst P 1, van der Steege G, de Boer RA, et al. MERIT-HF study. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol. 2007;49(13):1459–1464.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998–1006.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol. 2011;31(11):2383–2390.
   PubMed Web of Science ®Google Scholar
• Simionescu N, Niculescu LS, Carnuta MG, et al. Hyperglycemia determines increased specific MicroRNAs levels in sera and HDL of acute coronary syndrome patients and stimulates micrornas production in human macrophages. PLoS One. 2016;11(8):e0161201.
   PubMed Web of Science ®Google Scholar